AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$RPRX

Urist Marshall sold $239K of RPRX

Urist Marshall (EVP, Research & Investments) sold 4,126 shares of Royalty Pharma plc (RPRX) at $57.88 ($0.24M total) on 2026-09-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Urist Marshall
Published Sep 30, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RPRX
Neutral
medium confidence
Mentioned
$RPRX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RPRXNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, likely causing only slight price movement.

02

Market read

A routine insider sale with limited material impact; traders may note the transaction but no immediate action is required.

03

What to watch

The 10b5‑1 plan indicates the sale was pre‑scheduled, reducing informational asymmetry.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$RPRXNeutralMedium confidence
Context

SEC Form 4 shows EVP Urist Marshall sold 4,126 shares for $238,813 via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

Sale size is modest relative to market cap; insider is an EVP, but the transaction is pre‑arranged and disclosed promptly.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

No significant regional effect.

Global

Limited relevance beyond the stock itself.

Counterpoint

What could challenge this read

The sale could be interpreted as a lack of confidence, prompting a short‑term dip.

Key entities

  • Company
    Royalty Pharma plc

    US‑listed biotech firm (ticker RPRX).

  • Executive
    Urist Marshall

    EVP, Research & Investments at Royalty Pharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RPRX insider trading history →

Related articles

SEP 25
$RVMDMedAI 8/10

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Revolution Medicines (RVMD) received FDA breakthrough therapy designation for its pancreatic cancer drug, RASONQUE. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers diversified exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX is up 60% in a year, providing a balanced risk-reward option.

aol.com3 min
SEP 10
$RPRXMedAI 8/10

Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

Royalty Pharma (RPRX) reported that pelacarsen failed its Phase 3 trial, shifting financial focus to Spinraza royalties. The company provided $500M to Ionis (IONS) in 2023, with $150M allocated to pelacarsen. RPRX expects to recover its investment through Spinraza, aiming for a modest return. The failure limits pelacarsen's potential upside, and recovery depends on Spinraza's performance.

insidermonkey.com2 min
SEP 8
$NVSHighAI 8/10

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

Novartis AG (NYSE:NVS) stock fell sharply after its Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed the primary endpoint. The company also reported that the pelacarsen Phase 3 Lp(a)HORIZON trial for cardiovascular outcomes failed. Both Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) saw stock declines due to their ties with Novartis.

aol.com2 min
SEP 8
$NVSHighAI 8/10

Why Is Novartis Stock Falling Today? - Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty

Novartis (NYSE:NVS) stock fell sharply after Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed primary endpoint. The company also reported that the pelacarsen cardiovascular trial failed to meet its primary endpoint. Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) shares also declined due to the trial results. Novartis is evaluating the data and plans to discuss next steps with health authorities.

benzinga.com2 min